Moderna Inc (NASDAQ:MRNA) shares are trading higher on Monday. Piper Sandler boosted its price target on the stock to $69 from $63 while reiterating an Overweight rating. Here’s what you should know.
Multiple Pipeline Catalysts Ahead
Piper Sandler expects Moderna to generate $2.07 billion in product sales in 2026, driven largely by its next‑generation COVID vaccine, mNEXSPIKE, according to Investing.com.
The FDA is set to review Moderna's biologics license application for its seasonal flu vaccine, mRNA‑1010, with an Aug. 5 PDUFA date.
Moderna's combination flu and COVID vaccine, mRNA‑1083, is currently under review in Europe and Canada. The company also expects interim Phase III data for its norovirus vaccine, mRNA‑1403, in 2026. All of these catalysts set the stock up for outperformance, according to analysts at Piper Sandler.
Moderna ended 2025 with $8.14 billion in cash. The company holds more cash than debt, giving it ample flexibility to fund its broad pipeline and advance multiple late‑stage programs simultaneously.
Moderna recently reported fourth‑quarter results that topped expectations. The company posted an EPS loss of $2.11, beating the forecasted loss of $2.62, while revenue reached $678 million, ahead of the $662.84 million estimate.
What Other Analysts Are Saying
Moderna has seen a variety of ratings in recent months from different financial analysis firms, with a general upward trend in target prices.
Earlier in February, Goldman Sachs and Evercore ISI Group also maintained their ratings at Neutral and In-Line respectively, with Goldman Sachs setting a target price of $41.00 (from $36.00) and Evercore setting the target at $35.00 (from $28.00). RBC Capital also held its rating at Sector Perform but raised the target price to $30.00 from $25.00. Interestingly, UBS downgraded Moderna from Buy to Neutral on Jan. 7 and lowered the target from $40.00 to $34.00.
MRNA Price Action: Moderna shares were up 1.08% at $50.41 at the time of publication on Monday, according to Benzinga Pro.
Image: Pcruciatti/Shutterstock
